From: Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
[111In]In-AU-SAR-
M1
M2
M3
Average yield (%)
97.4 ± 2.6 (n = 7)
98.2 ± 1.8 (n = 5)
97.0 ± 3.0 (n = 6)
tR (min)
10.3
10
9.6
PBS
95.3 ± 1.3%
99.0 ± 0.5%
95.1 ± 1.7%
EDTA
96.4 ± 0.5%
98.1 ± 0.1%
91.4 ± 0.7%
p-value (PBS-EDTA)
0.28
0.03
0.02